Page History

SEND Leadership Team (SLT)

• Audrey Walker Ben Sefing (Industry Leader) (a)
• William Houser (Advisor/Past Leader) (a)
• Ben Sefing (Future/Next open seat (Next Industry Leader) (a)
• Lou Ann Kramer (CDISC Leader) (a)
• Dana Booth Dianna DiRusso (CDISC Project Manager, Foundational Standards) (a,b)

SEND Leadership Team Extended (SLTX)

• Audrey Walker, (Industry Advisor, Past Leader) (a)
• William Houser (Industry Leader Emeritus)

SEND Leadership Team Extended (SLTX)

• Ben Sefing (Industry Advisor, Past Leader) (a)
• Lou Ann Kramer (CDISC Leader) (a)
• Dana Booth Dianna DiRusso (CDISC Project Manager, Foundational Standards) (a,b)
• Audrey Walker (Industry Advisor, Past Leader) (a)
• William Houser (Industry Leader Emeritus)
• Brian Argo
• Mary Jo Brucker
• Sue DeHaven (PhUSE Liaison)
• Marc Ellison
• Stephanie Berry
• Anthony Fata
• Robert Friedman
• Jamie Gilliam
• Joseph Horvath
• Christy Kubin
• Louis Norton, Advisor
• Debra Oetzman
• Dan Potenta
• Ben Sefing 
• Erin Tibbs-Slone
• Michael Wasko (b)
• Fred Wood (b, Advisor)
• one open seat seat (b)
• FDA CBER Liaisons:
  • Virginia Hussong
  • Lisa Lin

• FDA CDER Liaisons
  • Jesse Anderson
  • Dave Epstein

(a

) = CDISC TLC (Technical Leadership Committee) member

(b

) = CDISC (Cross-team) Global Governance Group voting member

SEND Change Control Board (CCB)

• Jamie Gilliam (Leader)
• William Houser
• Lou Ann Kramer
• Louis Norton
• Debra Oetzman
• Ben Sefing
• Audrey Walker
• Michael Wasko
• Fred Wood
• FDA Liaison: Patricia Brundage

Stakeholders

• Regulatory Authorities
• Pharmaceutical Sponsors
• Nonclinical Research Scientists & Pathologists
• Contract Research Organizations
• Independent Consultants
• Information Technology Tool Developers
• Service Providers

Team Mission andScope

The CDISC SEND team develops standards that support both the regulatory submission of nonclinical data as well as the operational use and exchange of nonclinical data throughout the industry.

This team is responsible for overall development and maintenance of the production SEND Implementation Guides (IGs) and their alignment with the SDTM. 

SEND is one of the required standards for data submission to the FDA. Details on the requirements for the FDA are specified in the FDA’s Data Standards Catalog for IND, NDA, ANDA, and certain BLA submissions. For more information, please visit the FDA Guidance on Standardized Data.  

SEND Deliverables

The published versions of SEND deliverables are available to the public at: https://www.cdisc.org/standards/foundational/send

Upcoming Releases:

• SENDIG-DART v1.2 is to guide the implementation of toxicology studies that use juvenile animals, includes a new domain for Developmental Milestones (DP), and is targeted for June/July 2023
• SENDIG-GeneTox v1.0 is the first release to guide the implementation of genetic toxicology in vivo data, includes a new domain for Genetic toxicology in vivo (GV), and is targeted for June/July 2023
• SENDIG v4.0 is a major release, includes significant new functionality for many use cases, multiple domains new to SEND (CP, IS, NV, OE, SK), and is targeted for Q1 2025

SEND Subteams (leader)

SEND Controlled Terminology: Erin Tibbs-Slone 

SEND Conformance Rules: Christy Kubin

SEND CCB: Jamie Gilliam

Dermal / Ocular Toxicity : Brian Argo

Exposure : Wenxian Wang

Genotoxicity (Gene Tox) : Michael Wasko

Immunogenicity Specimen Assessments: Robert Friedman, Alex Kistner, Anthony Fata

Pharmacokinetic Concentrations & Parameters: Stephanie Berry

Safety Pharmacology: Christy Kubin

Trial Domain enhancements: Anthony Fata, Brandy Harter

Developmental & Reproductive Toxicology : Marc Ellison

Macro and Microscopic: Rachel Harper, Matt Hayes

Tumor Combinations: Charlotte Keenan

For more details on SEND initiatives, please see the SEND Home Wiki page at: SEND Home

Collaborations

The SEND Team maintains representatives on the many CDISC cross-team initiatives.  SEND also maintains 2 - 3 seats on the CDISC governance.  

The SEND team partners with the INHAND organization for pathology-related terminology (http://www.toxpath.org/inhand.asp).

SEND also has a strong presence on the FDA/PhUSE Computational Sciences Symposium (CSS) (http://www.phuse.eu/css), including several leadership positions and significant overlap in membership with the Nonclinical Topics working group.

Operating Model

• Full Team membership comprises all SEND members, with well over one hundred active members currently.
• Subteams are formed to manage long-term subject areas.
• Change Control Board (CCB) assesses and recommends action on changes requested regarding production SEND deliverables.
•SEND Leadership Team (SLT) - sets direction for the team and is responsible to CDISC leadership for the SEND Team; consists of past, current, and future team leaders.
•SEND Leadership Team - Extended (SLTX) assists in setting direction, with representation at the CDISC TLC and the CDISC GGG (Global Governance Group).

• Work-Streams, when needed, are for all tasks that are not within the scope of the listed subteams and expected to have a clear start and end (ie, shorter term need). Work-streams are initiated by the CCB or SEND leadership.

• Leadership Mentors - To develop new leaders on the SEND team, an experienced SLTX member will co-lead or mentor a newer leader for any new Work-Streams. All Subteams and Work-streams are governed by the SLTX and all work is reviewed by the Core Team.
• Business Integrators - are individuals who have demonstrated expertise with alignment across all domains and are often needed to review key concepts early in their development. They typically have an understanding of the CDISC and SEND strategy and approaches to certain concepts and designs and will look at impact beyond a domain, across domains and even across multiple "child" IGs.  Such individuals will often be needed in specific sessions at F2F weeks. This includes the following individuals:

William Houser, Lou Ann Kramer, Christy Kubin, Louis Norton, Debra Oetzman, Ben Sefing, Audrey Walker, Mike Wasko, Fred Wood, Craig Zwickl